Evidence map›Paper›PMID 31069957›Full record

Trial reportJournal of the International AIDS Society2019

End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study.

Elizabeth T Montgomery, Mags Beksinska, Nyaradzo Mgodi, Jill Schwartz, Rachel Weinrib, Erica N Browne, Nonhlanhla Mphili, Petina Musara, Manjeetha Jaggernath, Susan Ju and 4 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the International AIDS Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 4 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Elizabeth T MontgomeryWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.ORCID 0000-0002-5477-4445
Mags BeksinskaMRU (MatCH Research Unit), Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa.
Nyaradzo MgodiUniversity of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe.
Jill SchwartzCONRAD, Eastern Virginia Medical School, Arlington, VA, USA.
Rachel WeinribWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.
Erica N BrowneWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.
Nonhlanhla MphiliMRU (MatCH Research Unit), Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa.
Petina MusaraUniversity of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe.
Manjeetha JaggernathMRU (MatCH Research Unit), Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa.
Susan JuCONRAD, Eastern Virginia Medical School, Arlington, VA, USA.
Jenni SmitMRU (MatCH Research Unit), Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa.
Z Mike ChirenjeUniversity of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe.
Gustavo F DoncelCONRAD, Eastern Virginia Medical School, Arlington, VA, USA.
Ariane van der StratenWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.ORCID 0000-0001-8536-648X
RTI International · USUniversity of the Witwatersrand · ZAEastern Virginia Medical School · USUniversity of Zimbabwe · ZW

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

introductionAdherence to HIV prevention methods is a challenge, particularly for young women in Sub-Saharan Africa. End-user research during product development can inform modifiable factors to increase future uptake and adherence.

methodsPreferences for four vaginally inserted placebo HIV prevention methods were assessed among Zimbabwean and South African young women using a crossover clinical design. For each of months 1 to 4, participants were asked to use a pre-coitally inserted film, insert (vaginal tablet) and gel once/week for a month, and a monthly ring in a randomly assigned sequence. Participants subsequently chose one preferred product to use as directed for the final study month. Women ranked the four products from most preferred to least preferred at enrolment and after trying all products.

resultsA total of 200 women aged 18 to 30 (mean 23) were enrolled; 178 (89%) completed follow-up. At baseline, 41% of participants selected the gel as their most preferred product and 61% selected the ring as least preferred. During the crossover period, most (82% to 85%) self-reported using each product at least once a week, although only half the time with sex. Objective biomarker data confirmed adequate use of all products. After trying each product, rankings changed with the film, ring, insert and gel being selected by 29%, 28%, 26% and 16% respectively. Choice varied significantly by country (p < 0.001): More Zimbabweans chose the film (45%), and more South Africans chose the insert (34%). Among women choosing the ring, 88% reported using it every time with sex. By contrast, self-reported adherence was lower for "on-demand" (coitally associated) products, with 40% to 55% using them every time during sex (p < 0.001).

conclusionsPreferences for these four dosage forms varied before and after use, and both within and across countries - there was no clear favourite - indicating the need for a range of options for end-users The ring's popularity increased the most with use, was the second most preferred delivery system, and per self-report, provided more coverage during sex. These end-user perspectives provide important information to product developers and funding agencies.

Indexed as

AdolescentAdultConsumer BehaviorContraceptive Devices, FemaleCross-Over StudiesFemaleFollow-Up StudiesHIV InfectionsHumansSouth AfricaVaginal Creams, Foams, and JelliesYoung AdultZimbabweVaginal Creams, Foams, and JelliesadolescentsmicrobicidesPrEPSouth AfricawomenZimbabwe

Identifiers

PMID31069957
PMCPMC6506690
OpenAlexW2944214063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.